CA2930573C - Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses - Google Patents

Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses Download PDF

Info

Publication number
CA2930573C
CA2930573C CA2930573A CA2930573A CA2930573C CA 2930573 C CA2930573 C CA 2930573C CA 2930573 A CA2930573 A CA 2930573A CA 2930573 A CA2930573 A CA 2930573A CA 2930573 C CA2930573 C CA 2930573C
Authority
CA
Canada
Prior art keywords
cells
placental perfusate
human
certain embodiments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2930573A
Other languages
English (en)
French (fr)
Other versions
CA2930573A1 (en
Inventor
Jodi P. Gurney
Xiaokui Zhang
Stacy HERB
Robert J. Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celularity Inc
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of CA2930573A1 publication Critical patent/CA2930573A1/en
Application granted granted Critical
Publication of CA2930573C publication Critical patent/CA2930573C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2930573A 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses Active CA2930573C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
US61/905,076 2013-11-15
US61/905,077 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (2)

Publication Number Publication Date
CA2930573A1 CA2930573A1 (en) 2015-05-21
CA2930573C true CA2930573C (en) 2023-12-05

Family

ID=53058264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930573A Active CA2930573C (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Country Status (11)

Country Link
US (2) US20160279171A1 (https=)
EP (1) EP3068432A4 (https=)
JP (4) JP2016537362A (https=)
KR (3) KR20240023709A (https=)
CN (2) CN105916521A (https=)
AU (3) AU2014348454A1 (https=)
CA (1) CA2930573C (https=)
MX (2) MX2016006270A (https=)
RU (1) RU2016123361A (https=)
WO (1) WO2015073800A2 (https=)
ZA (1) ZA201603270B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2005094353A2 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory t cells and uses thereof
DK1957633T3 (en) * 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
NZ570614A (en) * 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
ZA200902233B (en) * 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
AU2008216748A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
CA2700613C (en) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
NZ592839A (en) 2008-11-21 2012-10-26 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010105144A2 (en) * 2009-03-12 2010-09-16 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
US20120177618A1 (en) * 2009-07-14 2012-07-12 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
LT2556145T (lt) * 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
ES2666746T3 (es) * 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
KR20130128438A (ko) * 2010-12-17 2013-11-26 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
US20120171180A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
JP2015526088A (ja) * 2012-08-13 2015-09-10 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
EP2909314B1 (en) 2012-10-19 2020-12-02 Celularity, Inc. Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
US20160279171A1 (en) 2016-09-29
KR20240023709A (ko) 2024-02-22
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
CA2930573A1 (en) 2015-05-21
JP2016537362A (ja) 2016-12-01
AU2022215291A1 (en) 2022-09-01
WO2015073800A2 (en) 2015-05-21
ZA201603270B (en) 2022-09-28
CN105916521A (zh) 2016-08-31
JP2022020622A (ja) 2022-02-01
CN113679740A (zh) 2021-11-23
RU2016123361A (ru) 2017-12-20
JP2024016037A (ja) 2024-02-06
AU2020202182A1 (en) 2020-04-16
KR20210121277A (ko) 2021-10-07
AU2014348454A1 (en) 2016-06-02
JP2020019777A (ja) 2020-02-06
WO2015073800A8 (en) 2015-12-17
MX2016006270A (es) 2016-09-07
KR20160098244A (ko) 2016-08-18
US20190117705A1 (en) 2019-04-25
EP3068432A2 (en) 2016-09-21
MX2021003799A (es) 2021-06-04
WO2015073800A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
Gutman et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit
JP5341525B2 (ja) 造血幹細胞の生着を増強するための方法および組成物
AU2022215291A9 (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
US20050118142A1 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
Kelly et al. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies
US20240408198A1 (en) Therapeutic compositions and methods for allogeneic hematopoietic stem cell transplantation
CN105143461A (zh) 血细胞制品及相关方法(Gen8)
Bacigalupo et al. Transplantation of HLA‐mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications
AU2018270407B2 (en) Selection and use of umbilical cord cell fractions suitable for transplantation
Basford et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells
US20100111905A1 (en) Methods for improved engraftment following stem cell transplantation
Sharma et al. A study of 120 umbilical cord whole blood transfusions in 77 patients with different clinical conditions
JP2010509360A (ja) 幹細胞移植を補助するためにＡＬＤＨｂｒ細胞を使用する方法
Eckstein et al. Joint Congress DGTI & DGI 2016, 7.-10. September 2016, Nürnberg, Abstracts
Reich-Slotky et al. Cellular therapy
Fry Cell separation and cryopreservation of cord blood fractions for immunotherapeutic applications
Pion A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy
Afreen et al. Evaluation of procedures for quantification of CD34 haematopoietic stem cells and viability studies in umbilical cord blood derived mononuclear cells.
BR112019024077B1 (pt) Método para preparar uma única unidade de sangue do cordão umbilical, e, artigo de fabricação

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191107

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260421

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421